18 July 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Issue of Equity in lieu of Non-Executive Director Fees
Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life sciences industry, today announces that it has issued 2,968,695 new ordinary shares of 0.1 pence each ("Ordinary Shares") at an average issue price of 0.3368 pence per Ordinary Share to settle Non-Executive Director fees.
Director Fee Shares
Tim Sykes has agreed to take shares in lieu of his Non-Executive Director fees, to be issued to him on a quarterly basis. Today's share issue will cover the period 1 April 2025 to 30 June 2025, and the price of the share issue is based on the volume weighted average daily closing share price for the relevant quarter.
Following this transaction, Tim Sykes' total beneficial interest in the Company is 11,639,758 Ordinary Shares, representing approximately 0.49% of the Company's issued share capital.
Total Voting Rights
An application will be made for the admission of these shares to trading on AIM, which is expected to become effective on or around 24 July 2025.
Immediately following Admission, the Company will have 2,394,731,620 ordinary shares of £0.001 each in issue. The Company does not hold any shares in treasury, and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in the Company under the Rules.
Additional Information
The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the purchase of ordinary shares by directors and other PDMRs in the Company.
NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||||||
| a)
| Name
| Tim Sykes | |||||||
| 2
| Reason for the notification
| ||||||||
| a)
| Position/status
| Non-Executive Director | |||||||
| b)
| Initial notification /Amendment
| Initial notification | |||||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||||||
| a)
| Name
| Aptamer Group plc | |||||||
| b)
| LEI
| 213800Y4XGH3WJNBE686 | |||||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||||||
| a)
| Description of the financial instrument, type of instrument | Ordinary shares of £0.001 each | |||||||
| | | ||||||||
| Identification code | GB00BNRRP542 | ||||||||
| | | ||||||||
| b)
| Nature of the transaction
| Award of shares | |||||||
| c) | Price(s) and volume(s) |
| | | | ||||
| d)
| Aggregated information | | |||||||
| | | ||||||||
| - Aggregated volume | 2,968,695 | ||||||||
| - Price | 0.3368p each | ||||||||
| | | ||||||||
| e)
| Date of the transaction
| 18 July 2025 | |||||||
| f)
| Place of the transaction
| Off market | |||||||
- Ends -
For further information, please contact:
| Aptamer Group plc Arron Tolley, Chief Executive Officer | +44 (0) 1904 217 404 |
| SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat | +44 (0) 20 3368 3550 |
| Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker | +44 (0) 20 3657 0050 |
| Northstar Communications Limited - Investor Relations Sarah Hollins | +44 (0) 113 730 3896 |
This announcement contains inside information for the purposes of the UK Market Abuse Regulation.
About Aptamer Group plc
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the $210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.